UBS Group AG - 30 Sep 2024 SCHEDULE 13G Report for Amneal Pharmaceuticals, Inc. Class A Common Stock, par value $0.01 per share (AMRX)

Filing Manager
UBS Group AG
Reporting Manager
UBS Group AG
Security
Amneal Pharmaceuticals, Inc. Class A Common Stock, par value $0.01 per share
Symbol
AMRX
Shares outstanding
311,476,536 shares
Disclosed Ownership
21,491,881 shares
Ownership
6.9%
Form type
SCHEDULE 13G
Filing time
30 Oct 2024, 11:04:34 UTC
Date of event
30 Sep 2024
Next filing
10 Feb 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"UBS Group AG disclosed 6.9% ownership in Amneal Pharmaceuticals, Inc. Class A Common Stock, par value $0.01 per share (AMRX) on 30 Sep 2024."

Quick Takeaways

  • UBS Group AG filed SCHEDULE 13G for Amneal Pharmaceuticals, Inc. Class A Common Stock, par value $0.01 per share (AMRX).
  • Disclosed ownership: 6.9%.
  • Date of event: 30 Sep 2024.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 30 Oct 2024, 11:04.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (1)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
UBS Group AG 6.9% 21,491,881 0 14,727 Andrew Johnson Director

Sponsored